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Abstract
Huntington’s disease (HD) is a rare neurodegenerative disease inherited in an
autosomal dominant pattern. Expanded cytosine-adenine-guanine (CAG) repeats
(polyQ) in the huntingtin gene cause the aggregates of abnormally expanded polyQ-
containing huntingtin protein, and striatal medium spiny neurons are shown to be
the most vulnerable. Affected patients develop cognitive, motor, and psychiatric
symptoms typically in middle age, and several pharmacological drugs are currently
used for symptomatic relief. Since the effect of current therapies is very limited and
there is no way to modify disease progression, there is an unmet need for developing
new therapies for HD. Toxin or genetic rodent models are widely used for drug
development, and large animal models are also available. Previous studies trans‐
planting cells originating from embryonic or fetal striatal tissues, neural stem cells,
mesenchymal stem cells, and induced pluripotent stem cells (iPSCs) in HD animal
models have shown the possibilities of clinical trials. Because clinical trials performed
using human fetal striatal cells have shown variable outcomes, future directions of
cell therapy in HD should consider the reconstitution of a functional dynamic
information-processing circuit without ectopic connections. Another major challenge
is to achieve controlled differentiation of embryonic stem cells or iPSCs into specific
neuronal phenotypes.
Keywords: Huntington’s disease, Animal models, Stem cells, Cell therapy, Trans‐
plantation
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1. Introduction
Huntington’s disease (HD) is an inherited neurodegenerative disease caused by expanded
CAG repeats in the huntingtin gene (Htt) on chromosome 4, which give rise to the formation
of aggregates of mutant huntingtin proteins. Affected patients gradually develop cognitive
decline, motor dysfunction (i.e., chorea or bradykinesia), and psychiatric disturbance that lead
to progressive disability and death within approximately 15–20 years of disease onset. Since
Huntington’s disease is inherited in an autosomal dominant manner (i.e., 50 % of children are
at risk) and the symptom onset occurs typically in middle age (median age, 35–40 years),
affected patients and their family members suffer from significant economical and psycho‐
logical burdens. Unfortunately, current therapies only target symptomatic reliefs and their
effects are very limited, so the need for developing new therapies for HD is in high demand.
It is important to rescue these vulnerable medium spiny neurons (MSNs) by slowing the
inexorable loss of striatal neurons and to delay the loss of striatal volume in affected patients,
in view of HD pathology where striatal MSNs are shown to be most affected. More recently,
stem cell strategy has been proposed to restore GABAergic striatal projection neurons into the
putamen and the caudate, thereby reestablishing the degenerating striatopallidal circuit.
According to previous research, transplanted cells originating from embryonic or fetal striatal
tissues in HD animal models are connected with appropriate targets in the host brain and
function both electrophysiologically and neurochemically to certain extents. Although clinical
trials based on these preclinical studies have been performed using human fetal striatal cells,
they have shown variable outcomes: some describe no benefit while others have indicated
some clinical improvements with reduced motor dysfunction or slowed disease progression.
However, because the use of human fetal tissues raise ethical issues and their genetic dissim‐
ilarity to the recipient is associated with the risk of immune rejection, other suitable non-fetal
cell sources of syngeneic donor tissue would be advantageous. Recently, although induced
pluripotent stem cells (iPSCs) generated from skin fibroblasts of HD patients have been
demonstrated as an alternative autologous cell source, these HD patient-derived iPSCs carry
genetic mutations, meaning that they have to be corrected to normal genes in order to be used
for cell therapy. For clinical applications, it will be essential to use transgene-free reprogram‐
med iPSCs that are derived from patients under good manufacturing protocol (GMP) condi‐
tions. In addition to this iPSC approach, it may be worthwhile to consider using mesenchymal
stem cells (MSCs), which are widely used in clinical trials, for the treatment of HD.
In this review, we describe the characteristics and limitations of current therapeutics and the
need for developing novel ones. Then, animal models commonly used in HD research, various
cell sources for transplantation, and the results and problems of preclinical and clinical studies
so far are also discussed. Finally, we discuss the future directions of HD research and the
clinical applications of stem cells. By doing so, we aim that the readers can acquire a thorough
knowledge of HD and an understanding of the need for and the current view of cell therapy
in HD.
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2. Characteristics of Huntington’s Disease
Huntington’s disease (HD) is a progressively deteriorating neurodegenerative disorder caused
by expanded polyglutamines (polyQs) with more than 35 CAG repeats in the huntingtin gene
(Htt) on chromosome 4. Htt protein is approximately 350 kDa and is composed of ten HEAT
(huntingtin, elongation factor 3, protein phosphatase 2A, and the yeast P13-kinase TOR1)
repeats, which form α-helical structures participating in intracellular transport [1]. Htt protein
is a ubiquitously expressed soluble protein [2]. Cytosolic Htt has been shown to bind micro‐
tubules and vesicles [3], whereas up to 5 % of Htt protein has been shown to locate within the
nucleus [4]. Htt protein is known for its involvement in microtubule-mediated vesicle trans‐
port, endocytosis, secretory process, and regulation of gene transcription/RNA trafficking, in
line with its location within the cell [5].
Interference with transcriptional regulation (e.g. CREB)
Decline of neurotransmitter receptors and brain-derived neurotrophic factor (BDNF) level
Interference with chaperone, proteasome (UPS), and autophagy activities
Disrupted axonal transport and synaptic transmission; cytoplasmic sequestration of transcription factors
Mitochondrial (complex I/II) dysfunction: calcium dysregulation/defective energy metabolism
Excitotoxicity via NMDA glutamate receptors
Activation of microglia and macrophages
Increased Kynurenine 3-monooxygenase (KMO) and 3-hydroxykynureine production: oxidative stress
Apoptosis/Necrosis
Table 1. Pathologic mechanisms of Huntington’s disease
It is still under debate whether the effect of mutant Htt protein is through a “gain-of-toxic
function” or a “loss of function,” and various mechanisms have been suggested to elucidate
the pathologic mechanisms of HD (Table 1). For example, mutant Htt that is translocated into
the nucleus can interfere with gene transcription via either direct binding to DNA or interacting
with several mediators including CBP (cAMP response element binding protein), NCoR
(nuclear receptor corepressor), SP1 transcription factor, basal transcription factors, and REST
(repressor element 1 silencing transcription factor) element [6, 7]. This reduced transcription
can decrease the level of brain-derived neurotrophic factor (BDNF) in the brain of HD patients.
Other loss-of-function mechanisms of Htt for disease pathogenesis have also been proposed
[8, 9]. It is worth noting that Htt is necessary for early embryonic development and Htt-null
mice demonstrate increased apoptosis [10]. A “gain-of-toxic-function” is another important
mechanism of toxicity of mutant Htt. For instance, because a highly expanded Htt gene in HD
leads to an Htt protein containing an abnormally expanded polyQ segment, toxic N-terminal
fragments of abnormal ß-sheets are formed [11]. Other posttranslational factors also promote
toxicity of mutant Htt, such as conformational change, aggregation propensity, cellular
localization, and clearance rate. Mutant Htt binds to mitochondria and alters mitochondrial
metabolism, which may result in energy defects, oxidative stress, and disturbed calcium
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homeostasis [12]. Moreover, protein clearance systems are shown to be impaired in HD
patients and in models [13]. Irrespective of the mode of patho-mechanism, Htt aggregates
within the cytoplasm and the nucleus, and selective neuronal cell loss and atrophy occur
predominantly in the striatum and the neocortex [14]. Altogether, HD develops mainly
through a “gain-of-toxic-function” mechanism from an abnormal conformation of mutant Htt
[15, 16].
HD is an inheritable disease passed down in an autosomal dominant manner. The prevalence
of HD is 4–10 per 100,000 in Western countries and approximately 0.4 per 100,000 in Asian
countries [17]. Disease onset is typically in middle age (median age, 35–40 years), but it can
also occur less commonly in juveniles and in old age depending on the CAG repeat number
and/or modifying genes and environmental factors [18]. The studies on the relationship
between CAG repeat number and disease manifestation demonstrated that there is an inverse
correlation between age at initial symptom onset and the length of the expanded CAG repeat
[19], and the correlation determines the age of onset with approximately 50–60 % variation [20,
21]. During HD, the disruption of the corticostriatal pathway, the main pathway affected,
causes progressive cognitive decline, motor dysfunction, psychiatric disturbance, and ulti‐
mately death within approximately 15–20 years [22]. Although CNS degeneration attributes
to these core symptoms, widespread pathology throughout the body may also contribute to
other general symptoms such as weight loss, skeletal muscle wasting, metabolic and endocrine
dysfunction, and dysfunction of cells of the hematopoietic lineage [13, 23].
Large aggregates of abnormally expanded polyQ-containing Htt protein, which form intra‐
nuclear inclusion bodies, are the pathological signatures of HD. Although the aggregates of
mutant Htt are widespread throughout the brain and body, the striatum-selective damage
encompassing the loss of striatal volume and up to 95 % loss of GABAergic medium spiny
neurons (MSNs) is seen in the corticostriatal pathway [24]. This striatal selectivity might be
explained by a possible involvement of a Ras homolog enriched in striatum (Rhes), a striatal-
specific protein that binds to mutant Htt and increases the cytotoxicity of Htt through SU‐
MOylation in HD pathogenesis [25]. Other than SUMOylation by Rhes, posttranslational
modifications generally on the N-terminal 17 amino acids of Htt, including phosphorylation,
ubiquitination, palmitoylation, and SUMOylation of huntingtin-associated (interacting)
proteins, have important roles in modulating the toxicity of Htt as well as the selective neuronal
loss [26]. Among the posttranslational modifications, phosphorylation has been shown as the
major process for modulating Htt. Phosphorylation at serines 13 and 16 of Htt has been
demonstrated to be protective against motor and psychiatric dysfunction and neuropathology
[27]. Palmitoylation of Htt at cystein 214 has been shown to enhance its membrane association,
whereas an expanded Htt shows less palmitoylation and an associated increase in neuronal
toxicity [28]. Small ubiquitin-like modifiers (SUMO) are proteins that covalently attach to and
detach from the target protein to modify their function, a process described as SUMOylation.
Several SUMO proteins are known to interact with Htt-related proteins (huntingtin-associated
protein 1 (HAP1) and transcription elongation regulator 1) [13], and SUMOylation of these
proteins by SUMO may be related to the pathogenesis of HD. Lastly, a disruption of BDNF
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support or an increased susceptibility to glutamatergic excitotoxicity of the neuronal circuit
between the cerebral cortex and the striatum can lead to HD pathogenesis [29].
In HD pathogenesis, selective striatal neuronal loss comes not only from cell-autonomous
toxicity but also cell-cell interactions. Cell-cell interactions occur between both interneuro‐
nal connections and between glial cells and neurons. In interneuronal connections, mutant
Htt  causes  increased  stimulation  of  extrasynaptic  glutamate  receptors  and  a  decreased
reuptake of glutamate by glia,  leading to enhanced excitotoxicity and metabolic toxicity.
Neuron and glia coculture experiments showed that expressing mutant Htt in glia triggered
neuronal  death  only  in  cells  expressing  mutant  Htt,  providing  evidence  for  the  role  of
mutant  Htt  in  neuronal  excitotoxicity  [30].  Further,  HD patient-derived astrocytes  alone
were  shown  to  replicate  HD  pathology  when  Htt  with  expanded  CAG  repeats  was
expressed [31].  Similarly,  in astrocytes,  transgenic expression of mutant Htt alone led to
HD-like symptoms or worsened disease progression when crossed into existing HD models
or even into normal mice [32]. In HD patients, microglia are activated in prodromal stages,
and then symptoms manifest in HD. The level of microglial activation has been shown to
correlate with disease severity and striatal loss in vivo [33, 34].
3. Current therapeutics in clinical practice and its limitation: Need for
developing novel therapeutics
Several pharmacological drugs are currently used for symptomatic relief of HD symptoms
such as hyperkinetic involuntary movements and mood disorders, and there is no way to
modify disease progression. For hyperkinetic involuntary movements including chorea,
myoclonus, and dystonia, dopamine-depleting agents (tetrabenazine), antipsychotics (halo‐
peridol, pimozide, clozapine, olanzapine, ziprasidone, aripiprazole, risperidone, and quetia‐
pine), benzodiazepines (clonazepam), anticonvulsants (sodium valproate and levetiracetam),
and botulinum toxin can be prescribed. Because tetrabenazine is not only a dopamine-
depleting agent but may also decrease brain serotonin and norepinephrine concentrations, it
potentially causes or aggravates depression [35]. Various neuroleptics (olanzapine, quetiapine,
risperidone, sulpiride, haloperidol, and clozapine) that are also used for psychiatric symptoms
should be administered with caution because they may induce tardive dyskinesia and other
adverse effects. Clozapine is well known for being costly and inducing irreversible agranulo‐
cytosis. For mood disorders, antidepressants (citalopram, fluoxetine, paroxetine, sertraline,
mirtazapine, and venlafaxine) and anxiolytics (benzodiazepines, propranolol, and clonidine)
are used [13]. A range of psychiatric drugs can alleviate some of the more overt disturbances
of mood and hyperactivity in HD; however, these drugs have limited effects and are associated
with side effects [36]. There is limited evidence in the literature for the use of acetylcholines‐
terase inhibitor (rivastigmine and donepezil) for cognitive dysfunction in HD [36, 37].
Behavioral  and social  interventions are often as effective as drug therapy for behavioral
difficulties. For instance, weight loss frequently leads to general weakening [38] and a higher
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body mass index has been associated with a slower rate of disease progression [39], meaning
that  adequate  nutrition  may  be  another  important  aspect  of  therapy.  Other  than  nutri‐
tion,  environmental  enrichment and physical,  speech,  and occupational  therapy are also
usually recommended to delay the onset  of  HD, some of  which have been validated in
mouse models [40, 41].
HD is one of few neurodegenerative diseases for which the diagnosis can be made long
before the onset of clinical symptoms by predictive genetic testing. This offers an opportu‐
nity to  intervene in the earliest  stages  of  neurodegeneration and thereby slow down or
arrest  disease  progression.  Many  drugs  targeting  various  mechanisms  underlying  HD
pathogenesis  have  been  tested.  However,  antiexcitotoxic  drugs,  such  as  riluzole  (an
antiglutamatergic drug) [42],  vitamin E [43],  idebenone and remacemide (an NMDA ion
channel blocker) [44], minocycline (a caspase-3 inhibitor and anti-inflammatory agent) [45],
and creatine (energy metabolites,  CREST-E trial)  [46]  have failed in clinical  trials  so far.
More favorable results from animal studies using memantine (an NMDA receptor antago‐
nist), coenzyme Q10 (a mitochondrial cofactor and an antioxidant), and ethyl eicosapentae‐
noate (an antioxidant) have been highlighted, but none of these compounds was successful.
Currently, reducing the expression of mutant Htt protein with RNA interference or antisense
oligonucleotides is the most promising candidate and other approaches of various mecha‐
nisms are being designed and under investigation [47].
4. Animal models of Huntington’s Disease
4.1. Rodent models in Huntington’s Disease
Rodent models have played an important role in providing experimentally accessible systems
to study various clinicopathological findings and pathogenesis of HD and to test potential
therapeutics of their efficacy [48]. From the late 1970s, several investigations started to generate
animal models of HD. Glutamate-related excitotoxin kainic acid (KA) and quinolinic acid (QA)
were used to induce the degeneration of striatal GABAergic projection neurons while pre‐
serving striatal afferents, thereby producing a model that resembles the neuropathologic
condition in HD [49, 50]. Because of marked epileptogenic side effects in KA model, QA model
is favored and currently used. Another toxic model of HD is made by producing defective
energy metabolism through toxins such as sodium azide, malonate, and 3-nitropropionic acid
(3-NP). For example, 3-NP-induced inhibition of mitochondrial complex II effectively produ‐
ces striatal lesions that were similar to the cell loss in HD [51, 52]. To mimic the chronic
progressive nature of human HD, chronic administration of metabolic toxin has been tried in
experimental primates; however, higher inter-animal variability and nonspecific striatal
damage in primates (NO replacement; just delete please) limit this approach [53]. Altogether,
despite their usefulness as mimics of striatal pathology and behavioral manifestations of HD,
toxin models were limited because it was not possible to study disease progression or to
replicate the widespread neuropathology observed in the human condition [54].
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After the discovery of the HD gene in 1993, genetic models of HD have been generated, and
over 20 different rodent models have been generated to date [55]. Genetic models provide
accurate and experimentally accessible systems in which to study the molecular pathogenesis.
Moreover, they provide an opportunity to test the effect/efficacy of candidate therapeutics and
explore their potential for clinical applications. Because the degree of overexpression of mutant
Htt protein plays a significant role in the phenotype in mice, genetic mouse lines have been
generated with varying degrees of phenotype by incorporating variations of mutant hunting‐
tin gene into the mouse genome. The mouse models fall into three categories (Table 2): (i) mice
that express truncated N-terminal fragment (exon-1 or exons 1 and 2) of the human Htt gene
containing polyglutamine mutations [56-60]; (ii) mice that express the full-length human HD
gene [61-65]; and (iii) mice with pathogenic human CAG repeats inserted into the existing CAG
expansion in murine Htt (knock-in models) [66-70]. Although all of these models develop the
typical findings of human HD, the degree and the progression to which the behavioral features
and pathological findings manifest differ, as well as the developmental speeds. Among them,
the R6/2 mice showed the most prominent motor, behavioral, and cognitive phenotypes as
well as marked weight loss and death by 13~15 weeks of age. In this strain, various mechanisms
of HD pathogenesis are demonstrated, including the intraneuronal nuclear inclusions;
impaired mitochondrial function [71]; abnormalities of glutamatergic, dopaminergic, and
cholinergic receptors in the striatum [72]; and abnormalities in synaptic plasticity in the
hippocampus [73, 74]. The full-length Htt gene (transgene) is incorporated into the mouse
genome via bacterial artificial chromosome (BAC) or yeast artificial chromosome (YAC).
Meanwhile, the phenotypes in the full-length Htt mutation model develop gradually over
several months and may survive as long as the wild-type animal [75]. This model is especially
valuable for studies on the proteolytic mechanism of full-length Htt, its clearance, and the
evaluation of the presymptomatic stages of HD. Among the full-length HD genetic models,
the YAC mouse model with 128 CAG repeats (YAC128) develops motor abnormalities,
composing of an initial hyperactivity and followed by difficulty in motor control from six to
12 months and then hypokinesia [76]. Further, other motor dysfunctions, including circling
behavior, hind limb clasping, and gait abnormalities, may be seen as early as three months [77].
Although the full-length models are genetically more accurate, the fragment Htt models have
been used more frequently for their aggressive phenotype, rapidly progressive disease course,
well-defined behavioral and pathological findings, and early death. Moreover, due to the
prolonged disease progression in the full-length Htt models, it is hardly possible to use
progressive morbidity and survival as endpoints [53].
While toxin models play a role in understanding mechanisms of excitotoxicity and mitochon‐
drial dysfunction in HD, they cannot replicate the progressive neurodegenerative course
characterized by the misfolding of the mutant Htt protein in HD. Alternatively, genetic animal
models provide a good platform to explore the progressive manifestation of neuropathology
and cognitive, behavioral, and motor dysfunction [48]. It also provides the platform to test
potential therapeutics for future translational research. However, standardization of sample
size, inclusion/exclusion criteria of mice, and the onset and duration of treatment, as well as
the outcome measurement of preclinical trials, are critical to compare the effectiveness of
candidate therapeutics [78].
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Model CAG-N Behavioral changes Neuropathology Survival
Transgenic models: Truncated N-terminal fragment
R6/1, Mouse
[56, 57]
116 Decreased anxiety
Significant weight loss
Abnormal motor performance
Reduced brain volume
Loss of striatal neurons
Htt aggregates
Reduced dopamine levels
12+ months
R6/2, Mouse
[58]
144–150 Dystonia with limb clasping
Significant weight loss
Reduced motor performance
Seizures, Diabetes
Gross brain atrophy
Progressive neuronal atrophy with
neuronal loss
Htt aggregates
Astrogliosis
Reduced dopamine levels
12–18 weeks
N171-82Q,
Mouse [59]
82 Weight loss
Abnormal motor performance
Limb clasping
Visuospatial memory loss
Gross brain atrophy
Atrophy and loss of striatal neuron
Htt aggregates
130–180 days
HD51, Rat
[60]
51 Significant weight loss
Deficient motor performance
Reduced anxiety
Cognitive deficits
Head dyskinesias
Enlarged ventricles
Striatal neuronal loss
Htt inclusion
NA
Transgenic mouse models: Full-length human Htt
YAC 128
[62, 76]
128 Hyperactivity (initial);
hypokinesia (later)
Abnormal circling behavior
Hindlimb clasping
Deficient motor performance
Gait abnormalities
Decreased striatal and cortical volume
Reduced striatal neuron area and
number
Progressive Htt aggregates
Slightly
decreased
BACHD
[64, 78]
97 (Mixed
CAA/CAG
repeat)
Significant reduction in motor
function (2 months)
Behavioral worsening (12
months)
Marked gross brain atrophy and brain
weight loss
Significant cortical and striatal volume
loss (12 months)
Degenerating neurons in striatum (12
months)
Htt inclusions in entire cortex; a few
small inclusions in striatum
Normal
lifespan
Hu97/18
[65]
97 Motor learning deficit (2
months)
Deficits in both spatial learning
and object recognition (9
months)
Increased stereotypy or
repetitive movement
Anxious and depressive-like
behaviors
Forebrain atrophy
Striatal volume loss
Cortical shrinkage and white matter
loss (12 months)
NA
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Model CAG-N Behavioral changes Neuropathology Survival
Knock-in mouse models: Full-length Htt
HdhQ111
[66, 68]
111 Gait impairment (13 months) Diffuse Htt activity (6 weeks) with
nuclear inclusions (12 months)
Astrogliosis (24 months)
Normal life
span
CAG140
[69]
140 Body weight loss
Hyperactivity (initial);
hypoactivity (later)
Gait abnormalities (12 months)
Nuclear and neuropil aggregates (8
months)
Diffuse Htt (2 months)
Neuronal loss
Normal life
span
CAG150
[70]
150 Body weight loss (70 weeks)
Motor performance deficits on
rotarod, gait, and beam balance
(70–100 weeks)
Striatal Htt aggregates (28 weeks)
Nuclear inclusions (37 weeks)
Reactive astrogliosis (56 weeks)
Loss of striatal neuron perikarya and
volume (100 weeks in homozygous
mice)
Normal life
span
Htt=huntingtin protein; NA=not available
Table 2. Rodent models of Huntington’s disease
4.2. Large animal models in Huntington’s Disease
Nonhuman primates are genetically more similar and have a more similar physiology to
humans than rodents, making them invaluable for modeling human disorders and for
developing therapeutic strategies. Nevertheless, only a limited number of works has been
reported in HD. The use of nonhuman primates is focused on the study of HD-like behavioral
manifestations, especially for chorea, and the development of potential therapeutics for HD.
In the case of nonhuman primate study, the toxin models using QA or 3-NP were most
commonly used [52, 79]. After the development of transgenic nonhuman primate models of
HD in 2008, the potentials of using large animals in HD research have been spotlighted. There
are three types of large animal models: a rhesus monkey (Macaca mulatta) [80], a miniature
pig model [81], and a sheep model (Ovis aries) [82]. The rhesus macaque and pig models were
generated using fragments of human mutant Htt and the sheep model using the full-length
human coding sequence of Htt. By injecting oocytes with lentiviruses expressing exon1 of Htt
carrying 84 CAG repeats, three transgenic monkeys were made, which survived for more than
two years and showed clinical features of HD, including dystonia and chorea [80]. Transcrip‐
tomic dysregulation was recently reported from peripheral blood samples, which is under
further clinical investigations [83]. The transgenic HD sheep model demonstrated a decreased
expression of DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of 32 kDa) at seven
months of age and a characteristic inclusion pathology in the brain at 18 months [84].On the
contrary, there were no aggregates in the brain even up to 16 months of age and no develop‐
ment of motor abnormalities in transgenic minipigs [85]. Because transgenic large animal
models have many advantages to understand the biology of HD and the development of
potential therapies, practical and ethical issues as well as preclinical works should be also
considered.
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5. Source of cell therapy for striatal transplantation in HD
A characteristic pathological feature in Huntington’s disease is a selective loss of medium spiny
projection neurons (MSN) in the striatum. Thus, cell therapy in HD is aimed at replacing the
MSN and making them functionally active by connecting them to the host neuronal network
[86]. To accomplish this, transplanted cells should survive, differentiate in vivo into the proper
cell type (i.e., MSN), be functionally active, and connect with appropriate target neurons,
thereby reestablishing the degenerating striatopallidal circuit [87, 88]. A number of potential
stem/progenitor cells have been studied that include embryonic stem cells; multipotent
progenitor cells from the embryo or fetus, which are already partially committed to a neural
lineage; cells from the umbilical blood; autologous or allogenic adult stem cells from various
tissues; and finally induced pluripotent stem cells [53]. The majority of cells used so far are
fetal neural stem/progenitor cells, but adult stem cells or iPSCs can be alternative cell sources
to fetal or embryo-derived stem cells. Before starting clinical trials, each cell type should be
shown to have efficacy and long-term safety in properly designed animal models of HD.
5.1. Fetal neural stem cells and fetal neural progenitor cells
Fetal neural stem cells (NSCs) are isolated from the fetal brain at various gestational periods
and from multiple brain regions [89]. After the collection of primitive cells and their short-term
expansion in vitro, these cells are transplanted into the lesioned brain of an adult rodent.
Majority of previous studies have used fetal neural progenitors (FNPs), which are expanded
as neurospheres prior to transplantation (Table 3), and the transplanted FNPs showed
evidence of differentiation into striatal-like cells [90]. Such neural differentiation depends on
the characteristics of fetal neural stem/progenitor cells to respond to signals in the developing
CNS [91]. For example, stem cells derived from the human fetal cortex (12 weeks post-
conception) were pretreated in culture media with ciliary neurotrophic factor (CNTF) and were
transplanted into QA-lesioned rats. Motor recovery and sustained striatal volume were
marked and the transplanted human stem cells differentiated into neurons and astrocytes with
substantial connections to endogenous cells [92]. Systemic injection of human NSC also
improved neuropathologic and behavioral abnormalities [93]. Because HD showed a selective
loss of MSNs in the striatum, induction of a GABAergic phenotype in immortalized striatal
NSCs was tried. These GABAergic phenotype-induced cells maintained neurite processes
connecting to endogenous neurons [94]. Mouse NSCs modified to secrete human nerve growth
factor (NGF) were transplanted into striatal QA-lesioned rats, and it was shown that the size
of lesion, the number of surviving striatal neurons, and the length of neurites were significantly
improved than sham-operated rats [95]. However, despite these successes based on fetal stem/
progenitors, the use of in vitro expanded fetal neural stem cells is limited because they lose
the capacity to differentiate into various neural cell types and tend to go into senescence after
several passages of culture [96]. Moreover, there is an intrinsic ethical issue associated with
the use of aborted fetal tissue. Recently, a cloned human striatal neural stem cell line
(STROC05) was transplanted in the R6/2 mouse model of HD, but the mouse model showed
a disappointing suboptimal clinicopathological improvement [97] (Table 3).
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Animal
model
Cells Histology Functional outcome Ref
Rat, QA
[U]
Human stem cell-
derived from fetal
cortex (pretreated with
CNTF)
Reduced striatal atrophy
Survive and differentiate into
neuron and glia
Connectivity with endogenous
neural cells
Improved motor performance
(cylinder test)
[92]
Rat, QA
[U]
Human NSC-derived
from fetal human
brain (systemic
injection)
Reduced striatal atrophy
NSC migration in and around
the damaged striatum
Migrated NSCs differentiated
into neurons and glias
Reduced ApoM-induced rotation [93]
Mice, QA
[U]
R6/2
Mouse NSC -
neurosphere and
dissociated cell
suspension
Increased survival of graft
when transplant at 2 days after
lesioning
No change on BDNF expression [94]
Rat, QA Noggin-primed
human NPC derived
from human ESC
Extensive migration and large-
scale differentiation
Increased the extent of neuronal
differentiation
NA [102]
R6/2 undifferentiated or
predifferentiated
DARPP-32 cells [B]
derived from human
striatal neural stem cell
line (STROC05)
Poor survival and neuronal
differentiation both in the
undifferentiated and
differentiated conditions
A few cells expressed the
neuronal marker beta-III-
tubulin.
NA [97]
Rat,
Lesions of
the dorsal
striatum
[U]
Homotopic neural
transplants
(GE or cortex from E15
rat embryos of same
strain)
Patches of positive DARPP-32
and tyrosine hydroxylase
Significantly higher extent of
DARPP-32 patches
Alleviated lateralised response
deficits
Prevented development of lateral
disparity
Restored speed of responding
back to pre-lesion levels
[131]
Rat, KA Fetal rat striatal
primordia
Differentiation to spiny neuron Restored synaptic potential [135]
Rat, QA Embryonic striatal
grafts (Lateral GE)
Reversed lesion-induced
increase in the cytochrome
oxidase activity of the Gp
Reduction of ApoM-induced
rotational asymmetry
[136]
Rat, Ch Embryonic striatum Innervated by host-derived
dopamine axons
Restored response of host
neurons
[137]
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Animal
model
Cells Histology Functional outcome Ref
Rat, KA Fetal striatal graft NA Restored striatal GABA overflow [138]
Rat, IA [U] Embryonic striatal
graft
NA Stimulation of GABA release [139]
R6/2 Striatal grafts Survival and differentiation of
grafts
Improved general locomotor
behavior
No significant functional
improvement
[132]
R6/1 Wild-type donor
cortex
NA No improvement [133]
Rat, 3-NP Human NSC
(transplantation before
3-NP administration)
Reduced damage to striatal
neurons
Increased BDNF expression
Improved motor performance [140]
Apo-M=apomorphin; BDNF=brain-derived neurotrophic factor; BM-MSCs=bone-marrow-derived mesenchymal stem
cells; Ch= Cholecystokinin-8-sulphate; CNTF=ciliary neurotrophic factor; DARP-32=dopamine- and cAMP-regulated
phosphoprotein of 32 kDa; ESC=embryonic stem cell; GABA=gamma-aminobutyric acid; GE=ganglionic eminence;
Gp=globus pallidus; IA=ibotenic acid; KA=kainic acid; 3NP=3-nitropropionic acid; MSN=medium spiny neuron; NA=not
available; NPC=neural precursor cell; NSC=neural stem cell; QA=Quinolinic acid; [B]=bilateral; [U]=unilateral
Table 3. Neural stem cell/progenitor cell-based treatment of HD in preclinical rodent models
5.2. Embryonic stem cell-derived neural progenitor cells
Embryonic stem cells (ESCs) are isolated and expanded from the inner cell mass of the
blastocyst-stage embryo. Because ESCs are very primitive and pluripotent, they can be
expanded in vitro indefinitely while retaining relatively stable cell characteristics [98]. Even
after expansion, they also retain substantial neurogenic potential [99]. Their ability to expand
and sustain neurogenic potential provides many advantages to be used in cell therapy;
however, there have been difficulties in inducing differentiation of ES cells into striatal cells,
which is especially important in HD. A report showed that mouse ES cells treated with retinoic
acid could differentiate into neuronal cells that could integrate and survive in the QA-lesioned
rat model of HD [100]. Another concern with the use of these cells is its potential for tumori‐
genicity, because even tiny numbers of undifferentiated cells at the time of transplantation
may develop into tumors later on. To overcome these limitations of ES cells, research has
shifted to using neural stem/precursor cells (NPCs). NPCs are a heterogeneous population of
mitotically active, self-renewing, and multipotent cells, which can be isolated from the embryo
[101]. Likewise, to use human neural precursors (hNP) derived from embryonic stem cells
(hESCs) in HD cell therapy, hNP is required to differentiate into neuronal cells, especially MSN,
in vivo. In vitro noggin priming can be an effective tool of hNP transplantation in HD
treatment. Noggin-primed hNP showed survival, extensive migration, and differentiation into
predominantly neuronal cells after transplantation in the QA-lesioned stratum of rats [102].
Recently, a protocol has been developed to obtain a high percentage of functional GABAergic
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neurons from mouse embryonic stem cells (mESCs) [103]. By combining an in vitro culture
and an in vivo differentiation protocol, striatal progenitors derived from hESCs were shown
to mature into DARPP-32-positive neurons in QA-lesioned rats [104]. Using neural precursor
cells with elimination of undifferentiated cells, ESC-based regenerative approaches may be
successful in treating HD patients. In addition to cell replacement potential, there is evidence
that transplantation of NPCs may modulate inflammatory reactions through a “bystander”
mechanism [105].
5.3. Non-neural stem cells
To avoid ethical problems, non-neural stem cells, such as adult stem cells or umbilical cord-
derived cells, have been used as alternative cell sources for HD treatment. Because adult stem
cells are relatively easy to harvest and autologous grafting is possible, there have been many
studies using mesenchymal stem cells (MSCs) of the bone marrow [106-108] or adipose tissue
[109, 110] in HD mouse models (Table 4). Although there is still debate about the possibility
of cell fusion events rather than true transdifferentiation, these non-neural stem cells are
known to have the capacity to differentiate into neurons after injection into the adult rodent
host [111]. Intrastriatal MSC transplants reduced motor and pathological deficits in a 3-NP-
lesioned rat and QA-lesioned mouse/rat HD models [106, 109, 112-115]. Genetically engineered
stem cells that produce trophic factors could also be a cell source for cell therapy [116-118].
When genetically engineered bone marrow-derived MSCs overexpressing neurotrophic
factors (NTFs), called NTF(+) cells, were transplanted into rat brains after QA injection, NTF(+)
cells survived, maintained their NTF-secreting phenotype, and exhibited improved behavior
and reduced striatal atrophy associated with QA lesions [119]. MSCs engineered to produce
BDNF also improved behavioral performance and reduced striatal atrophy when transplanted
in YAC128 mouse model of HD [120]. In addition, MSC-based studies take advantages of the
property of MSCs to modulate the brain environment toward neuroprotection [116]. Injection
of cell-free extracts of adipose-derived stem cells also demonstrates behavioral and patholog‐
ical improvements of R6/2 models in terms of HD pathology [121].
Animal
model
Cells Histology Lesion volume Functional outcome Ref
Rat, QA Rat BM-MSCs Reduced striatal
atrophy
Improved striatal
volume
NA [106]
Rat, QA Human adipose
MSCs
Reduced striatal
atrophy and apoptosis
Decreased lesion
volume
Reduced Apo-M induced
rotations
[109]
Mouse, QA Human BM
-MSCs
Increased cell
proliferation in
striatum
Reduced apoptosis
Decreased lesion
volume
Improved rotarod
performance
Extended survival
[113]
R6/2 mouse Human BM
-MSCs
Improved cell
differentiation
NA Improved survival [113]
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Animal
model
Cells Histology Lesion volume Functional outcome Ref
Rat, QA Human BM
-MSCs
Reduced striatal
atrophy
Increased level of
NTFs
Decreased lesion
volume
Reduced motor dysfunction [114]
R6/2 mouse Human adipose
MSCs
Reduced Htt
aggregates
Attenuated loss of
striatal neurons
Improved striatal
volume
Improved rotarod
Reduced clasping
Improved survival
[109]
Rat, 3NP Rat BM-MSCs Increased striatal
labeling in BDNF,
collagen type-I and
fibronectin
Prevented 3NP-
mediated ventricle
enlargement
Improved rotarod
Improved paw placement
[112]
Rat, QA Rat BM-MSCs Improved MSC
migration to lesion
Decreased lesion
volume
Regenerated striatal
network
Reduced Apo-M induced
rotations
[107]
Rat, QA Human BM-MSCs
engineered to
secret NTF
Survived after 6
weeks
Sustained NTF
secretion
Decreased lesion
volume
Reduced Apo-M induced
rotations
[119]
YAC 128
mouse
Human adipose
MSCs
Reduced striatal
atrophy
Improved striatal
volume
Improved rotarod
performance/ motor
function
[110]
Rat, QA Rat BM-MSCs NA NA Reduced Apo-M induced
rotations
Improved beam walk and
hang wire time
[108]
YAC 128
mouse
BM-MSCs
engineered to
produce BDNF
Reduced striatal
atrophy
Improved striatal
volume
Improved rotarod
performance
Reduced hindlimb clasping
[120]
Mouse, QA hESC-derived
GABA neurons
and their
progenitors
Repopulated
GABAergic cells,
connecting with
endogenous cells
NA Improved rotarod,
openfield, and tradscan
performance
[142]
Apo-M=apomorphin; BDNF=brain-derived neurotrophic factor; BM-MSCs=bone-marrow-derived mesenchymal stem
cells; hES=human embryonic stem cells; NA=not available; NTF=neurotrophic factor; QA=quinolinic acid; 3NP=3-
nitropropionic acid
Table 4. Mesenchymal stem cell-based treatment of HD in preclinical rodent models
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5.4. Induced Pluripotent Stem Cells (iPSCs)
Induced pluripotent stem cells (iPSCs) generated from somatic cells of patients can be used to
model different human diseases, thereby enabling disease investigation and drug develop‐
ment [122]. Since the generation of iPSCs does not involve the destruction of human embryos,
they can avoid the ethical issues related to the use of human ESCs [123]. In direct opposition
to embryonic/fetal tissue-derived cells, patient-derived iPSCs can avoid immune rejection as
well as ethical problems, and they can also serve as sources of transplantable cells in novel cell
therapies [124]. Recently, non-integrating episomal vectors were introduced into the cell by
electroporation, making transgene-free and virus-free iPSCs in a feeder-free environment
[125]. There are controversial results regarding formation of mutant Htt proteins in HD patient-
derived iPSCs (HD-iPSCs) [126, 127]. At least, HD-iPSCs can be differentiated into GABAergic
striatal neurons and make significant behavioral recovery without aggregation formation at
12 weeks after transplantation [127]. Nevertheless, as HD is a genetic disorder, correction of
HD mutations in HD-iPSCs is suggested to be an essential step before grafting to HD patients
[122]. With the advent of new gene editing technologies using zinc-finger nuclease (ZFN),
transcription activator-like effector nuclease (TALEN), and clustered regularly interspaced
short palindromic repeats (CRISPR)/Cas9, iPSCs that are derived from patients with gene
mutations may still be a plausible cell source for transplantation [128, 129]. A nucleofection-
based protocol adapted to single-cell dissociated feeder-free culture was established, and a
reversal of HD phenotype and striatal differentiation of gene-corrected HD-iPSCs in vitro and
in vivo are demonstrated [130]. If transgene-free reprogrammed iPSCs derived from patients
could be made under good manufacturing practice (GMP), they may provide a suitable source
for autologous transplantation in the future.
6. Results and problems of pre-clinical and clinical studies
6.1. Pre-clinical cell transplantation in Huntington’s Disease models
In view of HD pathology, it is important to rescue the vulnerable MSNs by slowing the
inexorable loss of striatal neurons. To rescue the damaged striatum, embryonic striatal tissues
were transplanted, and their survival, expression of a wide range of striatal markers, and the
recovery of motor and cognitive functions were demonstrated by many tasks of evaluation
both in HD toxin and genetic models (Tables 3–4) [131-133]. Although the extent of functional
improvement was relatively modest in transgenic animal models, it was shown that the
transplanted cells can connect with appropriate targets in the host brain [134] and function
both electrophysiologically [135, 136] and neurochemically [137, 138], indicating that striatal
grafts can yield a functional repair of striatal cell loss in HD [139]. The timing of cell trans‐
plantation should be also considered, as the pretreatment with human NSCs was shown to
rescue the motor impairment and neuronal damage caused by systemic 3-NP administration
[140]. When NSCs are transplanted after excitotoxin injection, the extent of neuronal recovery
could be different according to the time interval between excitotoxin injection and NSC
transplantation [94]. Another consideration on the cell transplantation is that transplanted cells
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should exhibit an MSN morphology, express MSN markers such as DARPP-32, and function
in vivo to recover the lost functions [141]. Recently, hESC-derived DARPP32-expressing
forebrain GABA neurons and their progenitors were implanted into QA-lesioned mice and
they were connected with endogenous dopaminergic and glutamatergic neurons [142]. In the
past two decades, clinical trials have been performed using human fetal striatal cells, and some
reports have indicated clinical improvement with reduced motor dysfunction or slowed
disease progression in some patients (Table 5). However, because human fetal tissue trans‐
plants inevitably raise ethical issues and risk of immune rejection, induced pluripotent stem
cells (iPSCs) generated from skin fibroblasts of HD patients [122], can serve as an autologous
cell source. HD-iPSCs could be differentiated into neural precursor cells and implantation of
those cells in the striatum of QA-lesioned rats; behaviors improved significantly; and Htt
aggregation was not formed at 12 weeks after transplantation [127]. In addition, various adult
stem cells also demonstrated behavioral and pathological improvement after transplantations
into toxin or transgenic rodent models (Table 4).
Donor
tissue
N Implant site Safety Efficacy Ref
VM or
WGE
4 NA [B] No pathological or
immunological response
Not possible to determine [143]
E12-13
WGE
2 CN cavity No surgical incidents or
subsequent SEs
Slow progression [144]
E8-9
LLGE
7 pcPu [B] 1 death from cardiac arrest,
3 subdural hematomas
Modest (NS) changes in motor tests at 12
months
Transplanted cells can survive and
integrate anatomically over 10 years
[146]
E9-12
WGE
4 CN + pcPu [B] Safe; no serious SE Stabilization or improvement in some
neurological indices
Prolonged graft survival with development
of striatal-like structure
[148]
E7.5-9
WGE
5 2 CN + 3 Pu
[B]
Safe procedure Motor and electrophysiol improvements
continue over 6 years
[145, 155]
E8-10
LGE
14 1 CN + 4 Pu
[B]
Safe; no serious SEs Benefit motor, limited neuropsychogic
tests
[149, 150]
E8-12
WGE
4 2 CN + 4 Pu
[U]
Only SEs related to
immunosuppression
Safety only, efficacy not reported [153]
Porcine
LGE
12 2 CN + 4 Pu
[U]
Safe; no serious SEs No change on TFC over 12 months [161]
CN = caudate nucleus; E = weeks of embryonic age; LLGE = lateral aspect of the lateral ganglionic eminence; NA=not
available; NS=not significant; pcPU = postcommissural putamen; Pu = putamen; SEs = side effects; TFC=total functional
capacity; WGE = whole ganglionic eminence; VM = ventral mesencephalon; [B] = bilateral implants; [U] = unilateral
implants.
Table 5. Clinical trials in HD patients
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6.2. Clinical trials of cell transplantation in Huntington’s Disease
On the basis of the encouraging results from animal studies, clinical trials using fetal neural
stem cells have been performed since 1990 (Table 5). In the early studies performed in Cuba,
Czechoslovakia,  and Mexico,  implantation protocols  and procedures were shown not  to
cause major complications or overt  side effects [143,  144].  Afterward, extensive series of
implants proved safety of the procedure in moderate stage of patients with functional and/
or  radiological  improvement  [145-148].  The  first  extensive  series  of  fetal  striatal  tissue
implantation was performed in Los Angeles, USA. The procedure was safe [149], and the
results  indicated motor and cognitive improvements in small  numbers of  patients [150].
Graft  survival  was  identified  by  magnetic  resonance  spectroscopy  [151].  Another  study
group in Tampa, Florida, USA, reported no overall improvement in motor function despite
absence of immune rejection [146].  However, when patients with the procedure-depend‐
ent  side  effect  (i.e.,  SDH)  were  excluded  from  the  result  analysis,  motor  scores  were
significantly  improved  after  transplantation,  and  the  postmortem  brain  analysis  in  one
patient  indicated  healthy  surviving  grafts  18  months  after  transplantation  and  good
differentiation into mature striatal-like tissue containing all striatal cell phenotypes [152].
Although three of the patients developed subdural hematoma after the surgery, this side
effect  could be avoided by careful  selection of  patients,  i.e.,  patients  without  significant
brain  atrophy,  for  operation.  Additional  safety  evaluation  trial  involving  the  United
Kingdom arm of the European network for striatal transplantation (“NEST-UK”) resulted
in  no  serious  side  effect  related  to  the  operation  [153].  This  group  also  suggested  a
comprehensive, logical yet pragmatic screening program for future neural transplantation
[154].  Meanwhile,  the efficacy of  fetal  striatal  cell  transplantation was shown in another
study group,  in  which four  patients  with HD have the stabilization or  improvement  of
motor indices after  fetal  neuroblast  implantation,  and the graft  has survived and devel‐
oped striatal-like structures in the host brain [148].
Another large-scale study has been going on in a multicenter trial in France (NCT00190450).
This study group is the first to undertake their trial in accordance with the standardized core
assessment protocol for intracerebral transplantation in Huntington’s disease (CAPIT-HD),
and detailed reports of transplantation in the first five patients have been published [145, 147,
155, 156]. In these series, three of the five patients showed motor and cognitive improvements
two years after intracerebral fetal neural grafts, which were correlated with recovery of brain
metabolic activity in grafted striatal areas and connected regions of the cerebral cortex,
measured by fluorodeoxyglucose-positron emission tomography. Restoration of the lost
sensory-evoked potentials is also noted. Furthermore, six years after transplantation, clinical
improvements became plateaued and then fade off variably within 4–6 years while maintain‐
ing stable cognitive function. Cerebral metabolism has also deteriorated progressively, sparing
the benefits in the frontal cortex and at the precise location of the grafts. This feature suggested
that fetal neural transplantation provides a period of several years of improvement and
stability, but not a permanent cure, and strategies of neuroprotection should be developed
further [145]. Although it is still controversial, a recent study raised a possibility that the
transplanted fetal striatal tissue can undergo disease-like neuronal degeneration after a decade
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of implantation [157]. Suboptimal long-term graft survival might be caused by the allograft
immunoreactivity, microglial responses, and cell-to-cell neurotoxicity [158]. Recently, donor-
specific anti-HLA antibodies were detected in six out of 16 patients with HD who received
human fetal striatal transplants [159]. These results underline the importance of careful
approach for developing cell-based therapy in HD.
Apart from using human fetal striatal tissue, there was a clinical trial using porcine-derived
striatal xenografts. In this case, the transplanted patients were treated with cyclosporin or a
monoclonal antibody directed against surface major histocompatibility complex I molecules
[160]. However, the surviving grafts were not detectable on MRI, and the treatment gave rise
to no functional benefit for the patients [161]. In the case of xenografts, fully effective immu‐
nosuppression strategies should be resolved.
In order to use neural stem cells for clinical trials, several aborted human fetal tissues are
required. Whether derived from elective or spontaneous abortion, there are sensitive ethical
and social issues associated with using human fetal tissues for transplantation. There are also
difficulties with accurate staging and collection (subject to appropriate ethical approval) and
storage of fetal tissues [162-164]. Therefore, in most cases, they would never meet the levels of
standardization and quality control required.
The delivery of trophic factors by genetically modified cells into striatum of patient has become
another therapeutic approach in HD. A variety of growth factors, including the neurotrophins,
fibroblast growth factor (FGF), ciliary neurotrophic factor (CNTF), glia-derived neurotrophic
factor (GDNF), and brain-derived neurotrophic factor (BDNF), have been found to promote
survival of striatal neurons in culture [117, 118, 165]. Direct injection of various trophic factors
incorporated into viral vectors has problems of standardization, regulation, and longevity of
treatment. Instead, implantation of engineered cells to express the desired transgene has been
suggested [166]. Intracerebral administration of a device formed by a semipermeable mem‐
brane encapsulating a BHK cell line engineered to synthesize CNTF has been tried. No sign of
CNTF-induced toxicity was observed, while improvements in electrophysiological results
were observed. However, depression was observed in three out of six HD patients, and
heterogeneous cell survival in the device hindered further clinical trials [166, 167]. Recently,
mesenchymal stem cell engineered to secrete BDNF has been suggested, due to its clinically
applicable characteristics [116].
7. Future directions of Huntington’s Disease research and clinical
applications
Therapeutic approaches using NSCs and other stem cell products for CNS diseases fall into
two broad categories: (i) regenerative/cell replacement to promote host tissue repair mecha‐
nisms and/or to replace missing or damaged cells and (ii) therapeutic delivery of macromole‐
cules (enzymes, cytokines, neurotrophins, drugs, etc.) for neuroprotection and/or stimulation
of repair. However, because HD is a progressive neurodegenerative disease and stem cells
might replace and protect only striatal neurons with limited capacity, stem cell therapy as
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means to stop disease progression might be insufficient [168]. As such, future directions of cell
therapy in HD should move beyond the replacement of lost neurons. To date, clinical trials
have been undertaken with fetal donor tissue in the striatum in HD. For therapeutic efficacy,
reconstitution of a functional dynamic information-processing circuit without ectopic connec‐
tions using transplanted stem cells is necessary. Another major challenge is to achieve
controlled differentiation of embryonic stem cells or induced pluripotent stem cells into
specific neuronal phenotypes, such as medium spiny neurons in the absence of aberrant
growth or tumor formation. Furthermore, novel approaches to provide therapeutic molecules
for neuroprotection should also be tried and verified.
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